Evidence map›Paper›PMID 39671089›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Serum CXCL-1 as a predictive biomarker for glucocorticoid resistance in adenoids of patients with adenoid hypertrophy.

Peiqiang Liu, Yu Xu

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Peiqiang LiuDepartment of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China.
Yu XuDepartment of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, China. xuy@whu.edu.cn.ORCID http://orcid.org/0000-0001-7751-6345

Funding

Fundamental Research Funds for the Central Universities 2042023kf0025Hubei key laboratory opening project 2023KFZ011National Natural Science Foundation of China 82271134National Natural Science Foundation of China 82401322Natural Science Foundation of Hubei Province 2023AFB229
6 · The paper itself

Abstract

purposeThe objective of this study was to elucidate the relationship between adenoid hypertrophy (AH) and glucocorticoid resistance, and to investigate the potential reasons for the suboptimal therapeutic response to intranasal glucocorticoids (INS) in pediatric patients with AH.

methodsThe present study enrolled a cohort of 110 patients diagnosed with AH, all of whom underwent adenoidectomy at Renmin Hospital of Wuhan University between June 2023 and September 2023. Immunohistochemistry and real-time quantitative polymerase chain reaction (RT-qPCR) were employed to assess the levels of inflammatory cytokines, and glucocorticoid receptors (GR, including GRα and GRβ) in adenoidal tissues. The Pearson correlation analysis was employed to ascertain the relationship between the levels of GR and inflammatory cytokines. The receiver operating characteristic (ROC) curve to evaluate the predictive efficacy of inflammatory cytokines in serum in assessing the glucocorticoid sensitivity and the expression of GR.

resultsCompared with the AH not associated with allergic rhinitis (AH-nAR) group, patients with AH-AR exhibit heightened eosinophilic inflammation and comorbid symptoms of AR. In patients with AH-nAR and those with poor glucocorticoid response, adenoidal tissues showed lower GRα expression and higher GRβ expression. Furthermore, IL-1β, CXCL-1, and CXCL-2 were simultaneously associated with a negative correlation with GRα, and a positive correlation with GRβ. Compared with IL-1β and CXCL-2, CXCL-1 in serum demonstrated a more significant predictive accuracy in discerning glucocorticoid sensitivity and evaluating the expression of GRα and GRβ.

conclusionIn patients with AH-nAR and those with poor glucocorticoid response, evidence of glucocorticoid resistance is observed within adenoidal tissues. Serum CXCL-1 may serve as a potential predictive biomarker for glucocorticoid resistance in AH patients, suggesting that surgical intervention should be more heavily considered for this cohort of patients.

Indexed as

AdenoidsChemokine CXCL1Drug ResistanceGlucocorticoidsAdenoidectomyAdolescentBiomarkersChildChild, PreschoolFemaleHumansHypertrophyMaleReceptors, GlucocorticoidRhinitis, AllergicBiomarkersChemokine CXCL1CXCL1 protein, humanglucocorticoid receptor alphaglucocorticoid receptor betaGlucocorticoidsReceptors, GlucocorticoidAdenoid hypertrophyAllergic rhinitisCXCL-1Glucocorticoid resistance

Identifiers

PMID39671089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.